文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

印度社区获得性呼吸道感染病原菌耐药监测(SOAR 2018-21):基于CLSI、EUCAST及PK/PD折点的结果

Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in India: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

该研究收集2018-21年印度6家实验室的肺炎链球菌(n=177)和流感嗜血杆菌(n=171)社区获得性呼吸道感染分离株,用CLSI肉汤微量稀释法测定MIC,并分别按CLSI、EUCAST和PK/PD折点判读敏感性。结果显示肺炎链球菌对青霉素的敏感率因折点而异(CLSI口服/EUCAST低剂量为41.2%,EUCAST高剂量/CLSI静脉为94.4%),仅头孢曲松在两种指南下均能覆盖两种细菌。持续耐药监测对指导经验性治疗重要。

要点

  • 肺炎链球菌青霉素敏感率因折点不同差异大:CLSI口服/EUCAST低剂量仅41.2%,高剂量折点达94.4%。
  • 阿莫西林、阿莫西林/克拉维酸、头孢噻肟、头孢曲松、左氧氟沙星和莫西沙星活性良好(≥89.8%,CLSI或PK/PD折点)。
  • 仅头孢曲松在CLSI和EUCAST两种指南下均覆盖肺炎链球菌和流感嗜血杆菌。

核心结论

  • 印度社区获得性呼吸道感染中肺炎链球菌和流感嗜血杆菌对部分抗生素仍保持敏感,但仅头孢曲松在CLSI和EUCAST两种折点下均覆盖两种病原。
  • 抗生素敏感性因所用折点不同而差异显著,持续监测对指导经验性治疗至关重要。

研究设计与样本

  • 2018-21年从印度4家医院实验室和2家私人实验室收集肺炎链球菌(n=177)和流感嗜血杆菌(n=171)社区获得性呼吸道感染分离株。
  • 采用CLSI肉汤微量稀释法测定MIC,并分别用CLSI、EUCAST和PK/PD折点判读敏感性。

主要发现

  • 肺炎链球菌仅41.2%对青霉素敏感(CLSI口服/EUCAST低剂量折点),但94.4%敏感(EUCAST高剂量/CLSI静脉折点)。
  • 肺炎链球菌对阿莫西林、阿莫西林/克拉维酸、头孢噻肟、头孢曲松、左氧氟沙星和莫西沙星活性良好(≥89.8%,CLSI或PK/PD折点),对头孢地尼和第二代头孢菌素活性较低(27.7%-64.4%),对四环素类、大环内酯类和甲氧苄啶/磺胺甲噁唑活性差(18.6%-31.1%)。
  • 流感嗜血杆菌91.8%为β-内酰胺酶阴性,按EUCAST和CLSI标准分别有13株和5株为β-内酰胺酶阴性氨苄西林耐药。
  • 流感嗜血杆菌对除甲氧苄啶/磺胺甲噁唑(23.4%)外的所有抗生素CLSI敏感率≥84.8%;EUCAST敏感率相似,但口服头孢呋辛无敏感株(CLSI为95.3%),氟喹诺酮类EUCAST敏感率≤29.8%(CLSI≥85.4%)。

关键数值与推荐

  • 肺炎链球菌青霉素敏感率:CLSI口服/EUCAST低剂量折点41.2%,EUCAST高剂量/CLSI静脉折点94.4%。
  • 肺炎链球菌对阿莫西林、阿莫西林/克拉维酸、头孢噻肟、头孢曲松、左氧氟沙星和莫西沙星敏感率≥89.8%(CLSI或PK/PD折点)。
  • EUCAST折点显示肺炎链球菌对高剂量头孢曲松和青霉素、莫西沙星及高剂量左氧氟沙星敏感率>90%。
  • 流感嗜血杆菌对甲氧苄啶/磺胺甲噁唑CLSI敏感率23.4%,对口服头孢呋辛EUCAST敏感率为0%(CLSI 95.3%),对氟喹诺酮类EUCAST敏感率≤29.8%(CLSI≥85.4%)。

临床怎么用

  • 在印度社区获得性呼吸道感染经验性治疗中,头孢曲松是唯一在CLSI和EUCAST折点下均覆盖肺炎链球菌和流感嗜血杆菌的抗生素。
  • 解读药敏结果时需注意所用折点(CLSI、EUCAST或PK/PD)对敏感性判定的显著影响,尤其是青霉素和氟喹诺酮类。
  • 四环素类、大环内酯类和甲氧苄啶/磺胺甲噁唑对肺炎链球菌活性差,不宜作为经验性选择。

局限性

  • 分离株仅来自印度6家实验室,样本量有限(肺炎链球菌n=177,流感嗜血杆菌n=171),代表性可能受限。
  • 未报告患者临床特征、感染部位及治疗结局,无法评估药敏结果与临床疗效的直接关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Antibiotic susceptibility determination of community-acquired respiratory tract infection (CA-RTI) isolates of Streptococcus pneumoniae and Haemophilus influenzae were collected from India (2018-21). METHODS: MICs were determined by CLSI broth microdilution; susceptibility data were interpreted using CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. RESULTS: S. pneumoniae (n = 177) and H. influenzae (n = 171) isolates were collected from four hospital laboratories and two private laboratories in India. Only 41.2% pneumococci were penicillin susceptible by CLSI oral/EUCAST low-dose breakpoints, but 94.4% were susceptible by EUCAST high-dose/CLSI IV breakpoints. Good activity (≥89.8%, CLSI or PK/PD breakpoints) was observed for amoxicillin, amoxicillin/clavulanic acid, cefotaxime, ceftriaxone, levofloxacin, and moxifloxacin. Cefdinir and second-generation cephalosporins were less active (27.7%-64.4%). Tetracyclines, macrolides and trimethoprim/sulfamethoxazole showed poor activity (18.6%-31.1%). EUCAST breakpoints indicated >90% susceptibility to high-dose ceftriaxone and penicillin, moxifloxacin and high-dose levofloxacin. Lower susceptibility to other cephalosporins and aminopenicillins was observed with EUCAST versus CLSI or PK/PD breakpoints. Most H. influenzae isolates (91.8%) were β-lactamase negative; 13 and 5 were β-lactamase-negative ampicillin-resistant following EUCAST and CLSI criteria, respectively. Antibiotic susceptibility was ≥84.8% (CLSI) for all antibiotics except trimethoprim/sulfamethoxazole (23.4%). Susceptibility by EUCAST was similar, except for cefuroxime (oral) with no susceptible isolates versus 95.3% by CLSI and ≤29.8% versus ≥85.4% for fluoroquinolones. CONCLUSIONS: Some therapeutic options against S. pneumoniae and H. influenzae from CA-RTI in India remain, but only ceftriaxone covers both bacterial species using both guidelines. Continued surveillance of antibiotic susceptibility is important to monitor changes and trends in susceptibilities and for guiding empiric therapy of CA-RTIs.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Torumkuney D, Veeraraghavan B, Patil N, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in India: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother. 2025. PMID: 41277342. doi:10.1093/jac/dkaf285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。